P2535 | BEDSIDE. Sipironolactone prevents the heart againts anthracycline cardiotoxicity. M. Akpek1, I. Ozdogru1 , M. Inanc2, O. Sahin1, A. Dogan1 , C. Yazici3 ...
Prevention – Rehabilitation: miscellaneous
P2535 | BEDSIDE Sipironolactone prevents the heart againts anthracycline cardiotoxicity M. Akpek 1 , I. Ozdogru 1 , M. Inanc 2 , O. Sahin 1 , A. Dogan 1 , C. Yazici 3 , V. Berk 2 , H. Karaca 2 , N. Kalay 1 , A. Oguzhan 1 . 1 Erciyes University, Department of Cardiology, Kayseri, Turkey; 2 Erciyes University, Department of Oncology, Kayseri, Turkey; 3 Erciyes University, Department of biochemistry, Kayseri, Turkey Aim: The most important adverse event of anthracyclines is cardiotoxicity and can limit the use of them. Spironolactone is an aldosterone antagonist and has antifibrotic and antioxidant effects. In the present study, we aimed to investigate the effects of spironolactone in the prevention of the cardiotoxic effects of the anthracycline. Materials and methods: A total of 83 female patients who diagnosed with breast cancer and planned anthracycline including chemotherapy regimen were enrolled in to the study. Study population were randomized as spironolactone and control group. Twenty five mg/day spironolactone was administrated to the patients in spironolactone group. Results: LVEF decreased from 67.0±6.1 to 65.7±7.4 (p=0.094) in the spironolactone group, while from 67.7±6.3 to 53.6±6.8 in control group (p200 mg/dl) and Body Mass Index >30 kg/m2 the second ones. Cox Multivariate adjustments were performed to account for differences in neoplasia and treatment. Results: 340 patients were included (197 male and 143 female): the most common pediatric cancer diagnosis were hematological malignancies (n=227) and brain tumors (n=51). After a median follow-up of 16.1 years, hypercholesterolemia was diagnosed in 87 CCS (25%), hypertriglyceridemia in 20 (6%) and obesity in 28 (8%). At multivariate adjustment, total body irradiation (TBI) and Growth Hormone Deficiency (GHD) increased the risk of both hypercholesterolemia (HR 2.7: 1.2-4.4 and 2.3: 1.1-4.9; all p
